Bio-Genex Laboratories, Inc.
BGNX
Other OTC0.00
USD
+0.00
- -
Bio-Genex Laboratories, Inc.
BGNX
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Bio-Genex Laboratories, Inc. engages in the design, development, and commercialization of advanced fully automated molecular pathology systems primarily for cancer diagnosis, prognosis, personalized medicine, and life science research. The company's core products include fully automated molecular pathology workstations and immunohistochemistry (IHC), in situ hybridization (ISH), fluorescence in situ hybridization (FISH), multiplex stains, microRNA and HPV probe systems, and related reagents and consumables. Its flagship product lines include the Xmatrx® systems, i6000™ systems, i500 Plus™, NanoVIP®, Neuvo, EZ-Retriever®, IHC primary antibodies, microRNA probes, and IHC/ISH detection kits, serving pathologists, histotechnologists, clinical labs, pharmaceutical, biotechnology, and academic research customers worldwide. Bio-Genex operates globally with headquarters and manufacturing in Fremont, California, and a regional center of excellence and manufacturing facility in Hyderabad, India, as well as customer service centers in Fremont, Hyderabad, and Shanghai, China. The company holds multiple regulatory certifications, including ISO 13485, ISO 9001, cGMP, and CE for in vitro diagnostics, supporting over 70 distributors across 47 countries. Founded in 1981, Bio-Genex focuses on providing cutting-edge automation technology that enhances efficiency and precision in tumor diagnostics and life science applications. In recent developments, Bio-Genex has launched several new primary immunohistochemistry antibodies targeting cancer diagnostics to expand its product offering. It also completed transition to direct sales and support responsibility for co-branded Xmatrx instruments and reagents, including expansion of its automated workflows to multiple molecular pathology assays. These moves align with its strategic focus on innovation and broader automation solutions in molecular pathology. Additionally, Bio-Genex has formed partnerships to integrate laboratory automation, such as the collaboration with Labtronics to interface automated systems, enhancing workflow capabilities and customer experience. Bio-Genex remains committed to clinical precision and improving cancer patient outcomes through advanced diagnostic technologies, supported by a global service infrastructure and a robust portfolio of patented and proprietary technologies.